NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis $3.71 -0.32 (-7.94%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$3.72 +0.01 (+0.27%) As of 11/13/2026 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Oramed Pharmaceuticals Stock (NASDAQ:ORMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oramed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.67▼$4.1250-Day Range$3.71▼$5.0152-Week Range$2.25▼$5.47Volume160,814 shsAverage Volume118,604 shsMarket Capitalization$154.32 millionP/E Ratio0.60Dividend Yield6.74%Price TargetN/AConsensus RatingBuy Company Overview Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments. Founded in 2006, Oramed has operations in the United States and Israel. Nadav Kidron serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Oramed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreORMP MarketRank™: 2.552534804305 of 5 starsOramed Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 537th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingOramed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOramed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Oramed Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is 0.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is 0.60, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.56.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.08% of the float of Oramed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 11.34, which indicates bearish sentiment.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently decreased by 7.42%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipOramed Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 6.20%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Oramed Pharmaceuticals is 4.06%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Oramed Pharmaceuticals' dividend. News and Social Media2.0 / 5News Sentiment0.28 News SentimentOramed Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $225,500.00 in company stock.Percentage Held by Insiders20.77% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.73% of the stock of Oramed Pharmaceuticals is held by institutions.Read more about Oramed Pharmaceuticals' insider trading history. Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORMP Stock News HeadlinesLifeward Reports 18% Third-Quarter AlterG Revenue Growth and Provides Update on ReWalk Commercial TransitionNovember 13 at 9:31 AM | quiverquant.comQOramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12 at 12:49 AM | marketscreener.comMDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 15 at 1:00 AM | Weiss Ratings (Ad)Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to Hold at Wall Street ZenNovember 7, 2026 | americanbankingnews.comOramed Pharmaceuticals (ORMP) Set to Release Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comOramed Pharmaceuticals consensus price target increased 12.00% to $7.14September 15, 2026 | msn.comOramed: Q2 Earnings SnapshotAugust 11, 2026 | chron.comOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetJune 25, 2026 | prnewswire.comSee More Headlines ORMP Stock Analysis - Frequently Asked Questions How have ORMP shares performed this year? Oramed Pharmaceuticals' stock was trading at $2.85 on January 1st, 2026. Since then, ORMP shares have increased by 30.2% and is now trading at $3.71. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) issued its quarterly earnings data on Thursday, November, 12th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.43 by $0.59. Who are Oramed Pharmaceuticals' major shareholders? Oramed Pharmaceuticals' top institutional investors include Aquamarine Financial Cayman Ltd (6.38%), BML Capital Management LLC (2.13%), State Street Corp (1.12%) and Ritholtz Wealth Management (0.16%). Insiders that own company stock include Joshua Hexter and Avraham Gabay. View institutional ownership trends. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), NIO (NIO), Intel (INTC) and Micron Technology (MU). Company Calendar Last Earnings11/12/2026Today11/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 3 days ago, ORMP's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ORMP CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees13Year Founded2006Profitability EPS (Trailing Twelve Months)$6.16 Trailing P/E Ratio0.60 Forward P/E RatioN/A P/E GrowthN/ANet Income$64.05 million Net MarginsN/A Pretax MarginN/A Return on Equity-7.57% Return on Assets-6.58% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.08 per share Price / Cash Flow44.42 Book Value$5.02 per share Price / Book0.74Miscellaneous Outstanding Shares41,597,000Free Float32,957,000Market Cap$154.32 million OptionableOptionable Beta1.31 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ORMP) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.